Latest news with #plc
Globe and Mail
7 days ago
- Business
- Globe and Mail
AstraZeneca's Real-Life Study on Benralizumab: Market Implications and Progress
AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Study Overview: AstraZeneca is conducting a non-interventional, prospective study titled A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life. The study aims to assess asthma control, health-related quality of life, lung function, and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in Germany. This research is significant as it evaluates real-life outcomes of benralizumab, providing insights into its effectiveness in routine clinical practice. Intervention/Treatment: The study focuses on benralizumab, a monoclonal antibody used to treat severe eosinophilic asthma. It aims to improve asthma control and quality of life by targeting and reducing eosinophils, a type of white blood cell involved in asthma inflammation. Study Design: This is an observational cohort study with a prospective time perspective. It involves a single-arm, multicenter approach where patients' asthma control and quality of life are monitored using various questionnaires and diaries over a 52-week period. Study Timeline: The study began on July 25, 2024, with its primary completion and estimated completion dates yet to be announced. The most recent update was submitted on July 15, 2025. These dates are crucial for tracking the study's progress and anticipating future findings. Market Implications: The ongoing study could influence AstraZeneca's stock performance by showcasing benralizumab's real-world effectiveness, potentially boosting investor confidence. As the asthma treatment market is competitive, positive results may enhance AstraZeneca's position against competitors, impacting market dynamics and investor sentiment. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Yahoo
16-07-2025
- Business
- Yahoo
What to Expect From STERIS' Next Quarterly Earnings Report
Mentor, Ohio-based STERIS plc (STE) provides infection prevention products and services worldwide. With a market cap of $22.2 billion, the company operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. STE is scheduled to report its Q2 earnings on Tuesday, August 5. Ahead of the event, analysts expect the company to report a profit of $2.32 per share, representing a 14.3% increase from $2.03 per share in the same quarter of the previous year. The company has surpassed or matched Wall Street's bottom-line estimates in each of the past four quarters. Dear Nvidia Stock Fans, Mark Your Calendars for July 16 Seeking Passive Income? This 'Strong Buy' Dividend Stock Yields 8.6%. How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For fiscal 2025, analysts expect STE to report earnings of $10.13 per share, up 9.9% from $9.22 in fiscal 2024. Moreover, the earnings are expected to rise 8.1% year-over-year to $10.95 per share in fiscal 2026. STE stock has grown 3.8% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 10.9% gain but outperforming the Health Care Select Sector SPDR Fund's (XLV) 10.3% decline over the same time frame. STE shares grew 8.5% in the trading session following the release of its Q4 earnings on May 14. The company's revenue increased 4.3% to $1.5 billion, surpassing the Street's estimates, mainly driven by a strong growth in its Healthcare and AST segments. Moreover, its adjusted EPS grew 6.2% year-over-year to $2.74 and surpassed the consensus estimates by 5.8%. Analysts' consensus opinion on STE stock is highly optimistic, with an overall 'Strong Buy' rating. Out of eight analysts covering the stock, six advise a 'Strong Buy' rating and two recommend a 'Hold.' The stock's average analyst price target is $272.14, indicating an 18.9% potential upside from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-06-2025
- Business
- Yahoo
Dr. Martens (LON:DOCS) Is Increasing Its Dividend To £0.017
The board of Dr. Martens plc (LON:DOCS) has announced that it will be paying its dividend of £0.017 on the 8th of October, an increased payment from last year's comparable dividend. This takes the annual payment to 3.4% of the current stock price, which unfortunately is below what the industry is paying. While the dividend yield is important for income investors, it is also important to consider any large share price moves, as this will generally outweigh any gains from distributions. Investors will be pleased to see that Dr. Martens' stock price has increased by 41% in the last 3 months, which is good for shareholders and can also explain a decrease in the dividend yield. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If it is predictable over a long period, even low dividend yields can be attractive. Prior to this announcement, the company was paying out 545% of what it was earning, however the dividend was quite comfortably covered by free cash flows at a cash payout ratio of only 16%. Generally, we think cash is more important than accounting measures of profit, so with the cash flows easily covering the dividend, we don't think there is much reason to worry. According to analysts, EPS should be several times higher next year. Assuming the dividend continues along recent trends, we estimate that the payout ratio could reach 34%, which is in a comfortable range for us. View our latest analysis for Dr. Martens The track record isn't the longest, but we are already seeing a bit of instability in the payments. Since 2021, the annual payment back then was £0.0244, compared to the most recent full-year payment of £0.0255. This works out to be a compound annual growth rate (CAGR) of approximately 1.1% a year over that time. It's encouraging to see some dividend growth, but the dividend has been cut at least once, and the size of the cut would eliminate most of the growth anyway, which makes this less attractive as an income investment. Growing earnings per share could be a mitigating factor when considering the past fluctuations in the dividend. Dr. Martens' EPS has fallen by approximately 43% per year during the past five years. Such rapid declines definitely have the potential to constrain dividend payments if the trend continues into the future. Over the next year, however, earnings are actually predicted to rise, but we would still be cautious until a track record of earnings growth can be built. Overall, we always like to see the dividend being raised, but we don't think Dr. Martens will make a great income stock. The company is generating plenty of cash, which could maintain the dividend for a while, but the track record hasn't been great. We would be a touch cautious of relying on this stock primarily for the dividend income. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Taking the debate a bit further, we've identified 4 warning signs for Dr. Martens that investors need to be conscious of moving forward. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
02-06-2025
- Business
- Associated Press
SolGold PLC Announces Voluntary Delisting from Toronto Stock Exchange
BISHOPSGATE, LONDON / ACCESS Newswire / June 2, 2025 / SolGold plc (LSE:SOLG)(TSX:SOLG) announces that it has applied for a voluntary delisting of its ordinary shares from the Toronto Stock Exchange (the 'TSX'). The delisting is intended to be effective as of the close of trading on June 18, 2025. The ordinary shares in the Company will continue to trade on the Main Market of the London Stock Exchange (the 'LSE') under the symbol 'SOLG'. Since SolGold obtained its TSX listing in 2017 to April 30, 2025, while daily trading activity in the Company's ordinary shares on such exchange increased somewhat, it only accounted for less than 3% of the aggregate trading volume on both platforms. As a result of these relatively low trading volumes on the TSX, the Company believes that the financial costs and administrative requirements associated with maintaining its TSX listing are no longer justified. Shareholder approval is not required for the delisting because the Company's ordinary shares trade on the LSE, which is an acceptable alternative market in accordance with Section 720(b) of the TSX Company Manual. Additional Information for Shareholders on SolGold's Canadian Registrar Following the delisting from the TSX, Canadian shareholders holding shares with their broker ('CDS participant') and wishing to trade their shares on the LSE will need for such shares to be made eligible to be transferred and settled through CREST, the United Kingdom ('UK') based share transfer and settlement system. CDS participants may initiate instructions to Computershare Trust Company of Canada ('Computershare') via its xSettle web service. Shares cannot be transferred and settled through CREST until a shareholder's CDS participant broker or the shareholder initiates a cross-border request. If the shares are held in certificated or Direct Registration form, as applicable, shareholders may instruct Computershare to arrange for the shares to be held by a CREST participant broker. This can be done by completing a 'Register Removal Request - Canada to United Kingdom' form, with valid CREST participant account details, and submitting such form to Computershare via email at [email protected]. For any questions on this process please contact Computershare's global transaction unit by phone at +1 (877) 624-5999. The Company intends to maintain CDS eligibility for its shares until July 18, 2025 in order to allow Canadian shareholders time to complete the process contemplated above. CONTACTS ABOUT SOLGOLD SolGold is a leading resources company focused on the discovery, definition and development of world-class copper and gold deposits and continues to strive to deliver objectives efficiently and in the interests of shareholders. See for more information. Follow us on X @SolGold_plc. CAUTIONARY NOTICE News releases, presentations and public commentary made by SolGold plc (the 'Company') and its officers may contain certain statements and expressions of belief, expectation or opinion which are forward looking statements, and which relate, inter alia, to the Company's plans to delist its ordinary shares from the TSX and the timing thereof, interpretations of exploration results to date and the Company's proposed strategy, plans and objectives or to the expectations or intentions of the Company's Directors, including the plan for developing the Project currently being studied as well as the expectations of the Company as to the forward price of copper. Such forward-looking and interpretative statements involve known and unknown risks, uncertainties, and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such interpretations and forward-looking statements. Accordingly, the reader should not rely on any interpretations or forward-looking statements, and save as required by the exchange rules of the TSX and LSE or by applicable laws, the Company does not accept any obligation to disseminate any updates or revisions to such interpretations or forward-looking statements. The Company may reinterpret results to date as the status of its assets and projects changes with time expenditure, metals prices and other affecting circumstances. This release may contain 'forward looking information'. Forward looking information includes, but is not limited to, statements regarding the Company's plans for developing its properties. Generally, forward looking information can be identified by the use of forward- looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved'. Forward looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking information, including but not limited to: transaction risks; general business, economic, competitive, political and social uncertainties; future prices of mineral prices; accidents, labour disputes and shortages and other risks of the mining industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, risks relating to the ability of exploration activities (including assay results) to accurately predict mineralization; errors in management's geological modelling and/or mine development plan; capital and operating costs varying significantly from estimates; the preliminary nature of visual assessments; delays in obtaining or failures to obtain required governmental, environmental or other required approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; the global economic climate; fluctuations in commodity prices; the ability of the Company to complete further exploration activities, including drilling; delays in the development of projects; environmental risks; community and non-governmental actions; other risks involved in the mineral exploration and development industry; the ability of the Company to retain its key management employees and skilled and experienced personnel; and those risks set out in the Company's public documents filed on SEDAR+ at Accordingly, readers should not place undue reliance on forward looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. The Company and its officers do not endorse, or reject or otherwise comment on the conclusions, interpretations or views expressed in press articles or third-party analysis. SolGold plc UK Company No. 5449516 ARBN 117 169 856 Email: [email protected] Website: Corporate Postal Office: PO Box 7059, Cloisters Square PO, Perth, WA 6850 Australia Registered office: 1 Cornhill, London, EC3V 3ND, UK Phone: +44 (0) 20 3807 6996 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: SolGold PLC press release
Yahoo
02-06-2025
- Business
- Yahoo
SolGold PLC Announces Voluntary Delisting from Toronto Stock Exchange
BISHOPSGATE, LONDON / / June 2, 2025 / SolGold plc (LSE:SOLG)(TSX:SOLG) announces that it has applied for a voluntary delisting of its ordinary shares from the Toronto Stock Exchange (the "TSX"). The delisting is intended to be effective as of the close of trading on June 18, 2025. The ordinary shares in the Company will continue to trade on the Main Market of the London Stock Exchange (the "LSE") under the symbol "SOLG". Since SolGold obtained its TSX listing in 2017 to April 30, 2025, while daily trading activity in the Company's ordinary shares on such exchange increased somewhat, it only accounted for less than 3% of the aggregate trading volume on both platforms. As a result of these relatively low trading volumes on the TSX, the Company believes that the financial costs and administrative requirements associated with maintaining its TSX listing are no longer justified. Shareholder approval is not required for the delisting because the Company's ordinary shares trade on the LSE, which is an acceptable alternative market in accordance with Section 720(b) of the TSX Company Manual. Additional Information for Shareholders on SolGold's Canadian Registrar Following the delisting from the TSX, Canadian shareholders holding shares with their broker ("CDS participant") and wishing to trade their shares on the LSE will need for such shares to be made eligible to be transferred and settled through CREST, the United Kingdom ("UK") based share transfer and settlement system. CDS participants may initiate instructions to Computershare Trust Company of Canada ("Computershare") via its xSettle web service. Shares cannot be transferred and settled through CREST until a shareholder's CDS participant broker or the shareholder initiates a cross-border request. If the shares are held in certificated or Direct Registration form, as applicable, shareholders may instruct Computershare to arrange for the shares to be held by a CREST participant broker. This can be done by completing a 'Register Removal Request - Canada to United Kingdom' form, with valid CREST participant account details, and submitting such form to Computershare via email at globaltransactionteam@ For any questions on this process please contact Computershare's global transaction unit by phone at +1 (877) 624-5999. The Company intends to maintain CDS eligibility for its shares until July 18, 2025 in order to allow Canadian shareholders time to complete the process contemplated above. CONTACTS Ryan Wilson Group General Counsel Tel: +44 (0) 20 3807 6996 Tavistock (Media) Jos Simson/Gareth Tredway Tel: +44 (0) 20 7920 3150 ABOUT SOLGOLD SolGold is a leading resources company focused on the discovery, definition and development of world-class copper and gold deposits and continues to strive to deliver objectives efficiently and in the interests of shareholders. See for more information. Follow us on X @SolGold_plc. CAUTIONARY NOTICE News releases, presentations and public commentary made by SolGold plc (the "Company") and its officers may contain certain statements and expressions of belief, expectation or opinion which are forward looking statements, and which relate, inter alia, to the Company's plans to delist its ordinary shares from the TSX and the timing thereof, interpretations of exploration results to date and the Company's proposed strategy, plans and objectives or to the expectations or intentions of the Company's Directors, including the plan for developing the Project currently being studied as well as the expectations of the Company as to the forward price of copper. Such forward-looking and interpretative statements involve known and unknown risks, uncertainties, and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such interpretations and forward-looking statements. Accordingly, the reader should not rely on any interpretations or forward-looking statements, and save as required by the exchange rules of the TSX and LSE or by applicable laws, the Company does not accept any obligation to disseminate any updates or revisions to such interpretations or forward-looking statements. The Company may reinterpret results to date as the status of its assets and projects changes with time expenditure, metals prices and other affecting circumstances. This release may contain "forward looking information". Forward looking information includes, but is not limited to, statements regarding the Company's plans for developing its properties. Generally, forward looking information can be identified by the use of forward- looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking information, including but not limited to: transaction risks; general business, economic, competitive, political and social uncertainties; future prices of mineral prices; accidents, labour disputes and shortages and other risks of the mining industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, risks relating to the ability of exploration activities (including assay results) to accurately predict mineralization; errors in management's geological modelling and/or mine development plan; capital and operating costs varying significantly from estimates; the preliminary nature of visual assessments; delays in obtaining or failures to obtain required governmental, environmental or other required approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; the global economic climate; fluctuations in commodity prices; the ability of the Company to complete further exploration activities, including drilling; delays in the development of projects; environmental risks; community and non-governmental actions; other risks involved in the mineral exploration and development industry; the ability of the Company to retain its key management employees and skilled and experienced personnel; and those risks set out in the Company's public documents filed on SEDAR+ at Accordingly, readers should not place undue reliance on forward looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. The Company and its officers do not endorse, or reject or otherwise comment on the conclusions, interpretations or views expressed in press articles or third-party analysis. SolGold plc UK Company No. 5449516 ARBN 117 169 856 Email: info@ Website: Corporate Postal Office: PO Box 7059, Cloisters Square PO, Perth, WA 6850 Australia Registered office: 1 Cornhill, London, EC3V 3ND, UK Phone: +44 (0) 20 3807 6996 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: SolGold PLC View the original press release on ACCESS Newswire Sign in to access your portfolio
